Share-Based Payments (Tables)

3 Months Ended

Jul. 31, 2022

Share-Based Payment Arrangement [Abstract]

Summary of allocation of share based compensation expense

Stock-based compensation expense was recognized as follows (table in thousands):

	Three Months Ended July 31,
	2022		2021
General and administrative	$	123	$	171
Sales and marketing	48		51
Research and development	3		6
Cost of oncology services	32		52
Total stock-based compensation expense	$	206	$	280

Summary of valuation assumptions for stock options

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2022 and 2021 were as follows:

	Three Months Ended July 31,
	2022	2021
Expected term in years	6	6
Risk-free interest rates	2.87%	0.82%
Volatility	62.58%	65.94% - 66.21%
Dividend yield	—%	—%

Summary of stock option activity

The Company’s stock options activity for the three months ended July 31, 2022 was as follows:

	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2022	1,617,324	40,915	1,658,239	$	4.51	4.9	$	6,131,000
Granted	78,000	—	78,000	7.57		9.90
Forfeited	(7,625)	—	(7,625)	7.73
Canceled	—	(1,875)	(1,875)	4.63
Expired	(4,584)	—	(4,584)	5.40
Outstanding, July 31, 2022	1,683,115	39,040	1,722,155	4.64		4.9	$	7,462,000
Vested and expected to vest as of July 31, 2022	1,683,115	39,040	1,722,155	4.64		4.9	$	7,462,000
Exercisable as of July 31, 2022	1,380,775	—	1,380,775	4.06		4.1	$	6,846,000